Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

>

Results for the Year Ended December 31, 2007

InterMune also reported financial results for the 12 months ended December 31, 2007. The net loss for the year was $89.5 million, or $2.52 per share, compared with a net loss of $107.2 million, or $3.22 per share in 2006.

Total revenue in 2007 was $66.7 million, compared with total revenue of $90.8 million in 2006, reflecting lower off-label revenues of Actimmune in IPF. Actimmune revenues totaled $53.4 million in 2007, compared with $90.3 million in 2006, a decrease of 41%. Revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191, was $13.3 million for the full year 2007, consisting of a $10.0 million development milestone payment and $3.3 million in amortization of the $70 million in initial milestone payments, compared to $0.5 million in 2006. The Roche collaboration was initiated in October 2006.

R&D expenses were $105.8 million in 2007, or 2% higher, compared with $103.8 million in 2006. The increase was primarily due to the much larger number of patients in the two Phase 3 CAPACITY studies during 2007 and the conduct of the Phase 1a and 1b studies of ITMN-191, partially offset by reduced costs related to the discontinuation of the INSPIRE program. G&A expenses were $29.6 million in 2007, compared with $40.4 million in 2006, a decrease of 27%, reflecting the impact of cost reductions related to the closure of the INSPIRE trial for Actimmune.

InterMune recorded income from discontinued operations in 2007 of $5.0 million, reflecting a clinical-related milestone received from Valeant Pharmaceuticals related to Infergen(R), which Valeant acquired from InterMune in December 2005.

In 2007, InterMune recorded approximately $10.2 million in charges for restructuring-related expense associated with the termination of the INSPIRE study in March. Approximately $6.8 million of the restructuring charges were related to the termination of an exi
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... JUPITER, Fla. , Aug. 18, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... and other proteins for the bioenergy, bio-based chemical, ... it has filed a Registration Statement on Form ... (the "SEC"). Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... heat during the production of electricity could be ... via a technique developed by researchers with the ... Laboratory (Berkeley Lab) and the University of California ... this technology include DOEs hydrogen fuel cell-powered Freedom ...
... in the Philadelphia suburbs, with unique new capabilities enabled by Masimo ... ... technologies, IRVINE, Calif., Jan. 10 Abington Memorial,Hospital and ... & Low Perfusion Pulse Oximetry, have announced the,completion of Philadelphia-based Abington ...
... Ky., Lexington, Ky., and Newport News, Va. Also ... ... spirit of excellence and remarkable achievements in its,community, Harborview Medical Center of ... is one of the most esteemed,honors of excellence in community service in ...
Cached Biology Technology:Feeling the heat 2Feeling the heat 3Feeling the heat 4Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 2Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 3Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 5Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 6
(Date:8/18/2014)... Half of the Earth,s land mass is made ... they are being transformed at an alarming rate. Woody ... and taking over, leading to a loss of critical ... of ecosystems to produce food specifically meat. ... Sciences led an investigation that quantified this loss in ...
(Date:8/18/2014)... Researchers from Aarhus University, Denmark, and the University of Wisconsin-Madison, ... exposure of species to both climate and land use change. ... species in the face of combined rates of climate and ... , Their results, which have just been published in ... vulnerable to losses in biodiversity and ecosystem function due to ...
(Date:8/18/2014)... the pygmy phenotype is probably a selective adaptation ... of researchers, but all African pygmy phenotypes do ... more recent adaptation than previously thought., "I,m interested ... very challenging environments," said George H. Perry, assistant ... rainforests are difficult for humans to live in. ...
Breaking Biology News(10 mins):Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3The double threat of climate and land use change enhances risks to biodiversity 2Pygmy phenotype developed many times, adaptive to rainforest 2
... 28, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a ... drugs to treat diseases of aging, announced today that ... developed novel drug candidates that offer a promising, new ... Diabetes, by targeting SIRT1, a gene that controls the ...
... Although a high standard of morality gives but a ... his children over the other men of the same ... give an immense advantage to one tribe over another. ... an evolutionary explanation for morality and pro-social behaviors individuals ...
... able to form abstract concepts. Friederike Range and ... shown for the first time that dogs can classify ... the same way that humans do. And the ... computer automated touch-screens, eliminating potential human influence. The ...
Cached Biology News:Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 2Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 3Group selection, a theory whose time has come...again 2Computer savvy canines 2
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Biology Products: